Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxosmithkline Intellectual Property Limited

Neil Stuart Garton

David Matthew Wilson

Michael David Barker

John Liddle

Christopher Roland Wellaway

Matthew Campbell

Clement Douault

Ann Louise Walker

Stephen John Atkinson

Robert John Sheppard

Hawa Diallo

Dominique Amans

Jessica Fanny Renaux

Paul Bamborough

Emmanuel Hubert Demont

Jonathan Thomas Seal

Vipulkumar Kantibhai Patel

Matthew John Lindon

Susan Marie Westaway

Romain Luc Marie Gosmini

Thomas George Christopher Hayhow

Francis Louis Atkinson

John Alexander Brown

Michael David Woodrow

Rino Antonio Bit

Natalie Hope Theodoulou

Tracy Jane Shipley

Alexander George Steven Preston

Matthew J Lindon

Christopher Wellaway

Compounds of formula (I): wherein X, Y, Rand R-Rare as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

Benzoimidazole derivatives as PAD4 inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors

The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

Furopyridines as bromodomain inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors

2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors

Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

Tetrahydroquinoline derivatives and their pharmaceutical use

The present invention relates to a compound of formula (I): or a salt thereof;which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors

Growing community of inventors

Stevenage, United Kingdom

Neil Stuart Garton